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Recognition and repair of damaged DNA occurs within
the context of chromatin. The key protein components of
chromatin are histones, whose post-translational modiﬁ-
cations control diverse chromatin functions. Here, we
report our ﬁndings from a large-scale screen for DNA-
damage-responsive histone modiﬁcations in human cells.
We have identiﬁed speciﬁc phosphorylations and acetyla-
tions on histone H3 that decrease in response to DNA
damage. Signiﬁcantly, we ﬁnd that DNA-damage-induced
changes in H3S10p, H3S28p and H3.3S31p are a conse-
quence of cell-cycle re-positioning rather than DNA da-
mage per se. In contrast, H3K9Ac and H3K56Ac, a mark
previously uncharacterized in human cells, are rapidly and
reversibly reduced in response to DNA damage. Finally, we
show that the histone acetyl-transferase GCN5/KAT2A
acetylates H3K56 in vitro and in vivo. Collectively, our
data indicate that though most histone modiﬁcations do
not change appreciably after genotoxic stress, H3K9Ac and
H3K56Ac are reduced in response to DNA damage in
human cells.
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Introduction
Protection of an organism’s genetic information is crucial for
maintaining cell viability and averting pathologies, such as
cancer (Aguilera and Gomez-Gonzalez, 2008). Cells possess
surveillance systems, collectively termed as the DNA-damage
response (DDR), to monitor and maintain genome stability.
The DDR uses sensor proteins that recognize DNA damage,
promote DNA repair and initiate ‘checkpoint’ events that
control cell-cycle progression (Harper and Elledge, 2007). In
human cells, DDR proteins include the PI3-kinase-related
protein kinases (PIKKs) ataxia telangiectasia mutated
(ATM), ATR (ATM and Rad3 related) and DNA-PK (DNA-
dependent protein kinase). Upon activation, these kinases
then trigger the phosphorylation of over 700 identiﬁed
protein targets that regulate multiple cellular processes,
including DNA repair, cell-cycle progression and transcription
(Matsuoka et al, 2007). Well-characterized PIKK phospho-
rylation sites include Ser-15 of p53, Ser-966 of SMC1 and
Ser-139 of H2AX.
Although analyses of the DDR have traditionally focused
on the nature of the DNA damage itself, it is clear that the true
initiating substrate for the DDR in vivo is damaged DNA in
the context of chromatin (Downs et al, 2007; Groth et al,
2007; Escargueil et al, 2008). The basic unit of chromatin is
the nucleosome, which contains approximately 146 base
pairs of DNA wrapped around an octamer of eight core
histones, comprising two copies each of the four core his-
tones: H2A, H2B, H3 and H4. Chromatin functions are
inﬂuenced by reversible histone post-translational modiﬁca-
tions (PTMs), which include methylation, ubiquitylation,
sumoylation, phosphorylation and acetylation (Kouzarides,
2007). Each of these reversible modiﬁcations is regulated by
speciﬁc enzymes and has the capability of changing dynami-
cally. For example, acetylation of lysines is accomplished by
histone acetyl transferases (HATs), whereas deacetylation of
lysines is catalysed by histone deacetylases (HDACs).
Histone modiﬁcations are best understood for their ability
to regulate transcription (Berger, 2007), but it is becoming
increasingly clear that histone PTMs also function in the DDR
(Downs et al, 2007; Groth et al, 2007; Escargueil et al, 2008).
The best characterized example of this is the PIKK-mediated
phosphorylation of the C-terminal tail of histone H2AX
(called gH2AX) (Rogakou et al, 1998), which is required to
localize DDR proteins, such as MDC1 and 53BP1, to sites of
DNA damage (Celeste et al, 2003; Bekker-Jensen et al, 2006;
Stucki and Jackson, 2006). gH2AX also leads to the recruit-
ment of chromatin-modifying enzymes, including HATs,
HDACs, kinases, phosphatases, E3 ubiquitin ligases and
chromatin remodeling complexes, to sites of DNA damage
(Thiriet and Hayes, 2005; Huen et al, 2007; Kolas et al,2 0 0 7 ;
Mailand et al, 2007). In addition, histone H2B Ser-14 is
rapidly phosphorylated at the sites of DNA damage
(Fernandez-Capetillo et al, 2004) and the maintenance of
histone H3 phosphorylation on Thr-11 by CHK1 is lost upon
DNA damage, which is implicated in the transcriptional
regulation of certain genes that control cell-cycle progression
(Shimada et al, 2008). Interestingly, after ultraviolet (UV)
damage, all histones display a rapid hyper-acetlyation phase
followed by a hypoacetylated state, although the speciﬁc
histone marks that changed were unidentiﬁed (Ramanathan
Received: 16 January 2009; accepted: 26 March 2009; published
online: 30 April 2009
*Corresponding authors. KM Miller or SPJackson, The Gurdon Institute,
University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK.
Tel.: þ44 1223 334108; Fax: þ44 1223 334089;
E-mails: k.miller@gurdon.cam.ac.uk or
s.jackson@gurdon.cam.ac.uk
1These authors contributed equally to this work
The EMBO Journal (2009) 28, 1878–1889 | & 2009 European Molecular Biology Organization|Some Rights Reserved 0261-4189/09
www.embojournal.org
The EMBO Journal VOL 28 | NO 13 | 2009 &2009 European Molecular Biology Organization
 
EMBO
 
THE
EMBO
JOURNAL
THE
EMBO
JOURNAL
1878and Smerdon, 1986). Additionally, H4K16 acetylation and
H2A ubiquitylation have been shown to increase after ioniz-
ing radiation (IR) (Gupta et al, 2005; Huen et al, 2007;
Mailand et al, 2007). Collectively, these data establish that
multiple types of histone PTMs are involved in the DDR and,
moreover, raise the prospect that additional DDR-responsive
chromatin modiﬁcations await identiﬁcation.
Results
Identiﬁcation of DNA-damage-responsive histone PTMs
To screen for changes in histone modiﬁcations in response to
DNA damage, we surveyed the global histone modiﬁcation
landscape with PTM-speciﬁc antibodies in extracts from
human osteosarcoma (U2OS) cells untreated or treated with
hydroxyurea (HU) or phleomycin. Fluorescence-activated cell
sorting (FACS) analyses revealed that HU-treatment generated
an enrichment of cells in S-phase, as expected because HU
reduces deoxyribonucleotide levels, leading to S-phase arrest
with DNA damage (Supplementary Figure 1A). In contrast,
phleomycin treatment yielded a normal cell-cycle proﬁle as it
produces DNA double-strand breaks (DSBs) at all cell-cycle
stages (Supplementary Figure 1A). Importantly, both treat-
ments generated DNA damage effectively, as evidenced by
robust gH2AX production and strong phosphorylation of p53
Ser-15 and SMC1 Ser-966 (Figure 1A). Next, we subjected
samples from mock and DNA-damage-treated cells to western
immunoblotting with a panel of 32 commercially available
antibodies against known histone modiﬁcations (Figure 1C;
Supplementary Table 1). To only analyse chromatin-asso-
ciated histones and to lower non-speciﬁc antibody staining,
we used acid-extracted histones (Shechter et al, 2007).
Furthermore, although commercially available antibodies
against histone PTMs are generally assumed to be highly
speciﬁc, we included bacterially produced recombinant core
histones that lack PTMs in our screen to assess whether any
of the antibodies cross-reacted with unmodiﬁed histones
(Supplementary Figure 1B). Thus, each antibody was tested
for reactivity against four samples: one comprised of recom-
binant histones H2A, H2B, H3.1 and H4; one derived from
mock-treated cells; one derived from HU-treated cells and one
derived from phleomycin-treated cells. Importantly, samples
contained very similar amounts of histone proteins as deter-
mined by Coomassie staining (Figure 1B).
As shown in Figure 1C, results from the screen fell into
four distinct categories. Category I consisted of three anti-
bodies that recognized recombinant histones and three anti-
bodies that recognized PTMs on a different histone than the
antibody was raised against, and were, therefore, deemed
non-speciﬁc. Category II consisted of 10 antibodies whose
signals were unaffected by DNA damage. Category III
contained eight antibodies whose signals changed in re-
sponse to DNA damage, but differed in their responses to
HU and phleomycin. Category IV comprised antibodies
whose signals changed similarly in response to both HU
and phleomycin treatment. This latter group consisted of
antibodies directed against dimethylated histone H3 Arg-2
(H3R2Me2), acetylated H3 Lys-9 (H3K9Ac), acetylated H3
Lys-14 (H3K14Ac), acetylated H3 Lys-56 (H3K56Ac), phos-
phorylated H3 Ser-10 (H3S10p), phosphorylated H3 Ser-28
(H3S28p) and phosphorylated H3.3 Ser-31 (H3S31p). We
selected this group for further investigation as these histone
marks were similarly responsive to both replicative and DSB-
induced DNA damage. In addition, although the signal for H3
phosphorylation on Thr-11 (H3T11p) did not change appre-
ciably in the initial screen, we included this modiﬁcation in
our subsequent studies as it has recently been linked with the
DDR (Shimada et al, 2008).
Analysis of histone PTMs after DNA damage
and throughout the cell cycle
To substantiate and expand on the above ﬁndings, histone
PTMs selected for further investigation were analysed for
their responses to various DNA-damaging agents including
phleomycin, IR, UV, methylmethane sulfonate (MMS), camp-
tothecin (CPT) and hydrogen peroxide (H2O2). In these
experiments, no reproducible changes in H3K14Ac and
H3R2Me2 levels were observed after DNA-damage induction
in U2OS cells (Figure 2A, left panel; note that all treatments
generated DNA damage, as evidenced by gH2AX production).
As these PTMs also did not change appreciably on phleomy-
cin treatment of human HeLa cells (Figure 2B, right panel),
H3K14Ac and H3R2Me2 were not analysed further. In con-
trast to the above data, with the exception of H3T11p, all of
the other histone PTMs selected for further investigation
displayed varying decreases on DNA-damage induction both
in U2OS and HeLa cells (Figure 2A). Notably, these data
indicated that the proﬁles of H3 phosphorylation changes
after DNA-damage induction were similar to one another and
differed from the less pronounced reductions observed for
H3K9Ac and H3K56Ac. For example, though CPTand IR had
minor effects on H3K9Ac and K56Ac levels, these treatments
substantially reduced the levels of H3 phosphorylations
(Figure 2A). Collectively, these results suggested that changes
in H3 phosphorylations and H3 acetylations deﬁne two
distinct responses to DNA damage.
A major response to DNA damage is cell-cycle arrest
(Harper and Elledge, 2007), raising the possibility that the
histone PTM changes described above could reﬂect altera-
tions in cell-cycle distribution rather than a response to DNA
damage per se. To explore this possibility, we synchronized
U2OS cells in G1/S with a double-thymidine block, released
them back into the cell cycle and monitored cell-cycle pro-
gression by FACS analysis (Figure 2B, top panel). Western
blotting analyses revealed that H3S10p, H3S28p and
H3.3S31p were signiﬁcantly increased in samples enriched
for mitotic cells (Figure 2B, bottom panels, 12 and 14h time
points). Furthermore, and consistent with an earlier report
(Shimada et al, 2008), H3T11p was detectable throughout the
cell cycle, but increased during mitosis. In contrast, the variation
of H3K9Ac and H3K56Ac throughout the cell cycle was mini-
mal. This, therefore, suggested that the observed DNA-damage-
dependent reductions of H3 phosphorylations might be a con-
sequence of the levels of these PTMs being highest in mitosis, a
cell-cycle stage that is lost after DNA damage (Hartwell and
Weinert, 1989; Lukas et al, 2004). In contrast, these results
indicated that the reduction of H3 acetylations in response to
DNA damage could not simply be explained by DNA damage
leading to altered cell-cycle distributions.
Analysis of histone H3 phosphorylations
after DNA damage
As H3S10p, H3S28p and H3.3S31p occur primarily in mitosis
(Figure 2B), this confounded our interpretation of their
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To circumvent this limitation, we arrested cells in pro-meta-
phase with the microtubule poison nocodazole and ascer-
tained the effect of DNA damage on H3 phosphorylations in a
position of the cell cycle when these histone PTMs are highly
abundant. For comparison, mitotically arrested cells were
released into the cell cycle and then analysed for DNA-
damage-induced changes in H3 phosphorylations when
in the G1- and S-phases of the cell cycle (Figure 3A;
Supplementary Figure 2). Signiﬁcantly, none of the H3 phos-
phorylations analysed changed after DNA damage in noco-
dazole-arrested cells, even though the cells exhibited gH2AX
induction (Figure 3A). Furthermore, cells in G1- and S-phase
had substantially lower levels of H3 phosphorylations com-
pared with nocodazole-arrested cells, supporting our ﬁndings
that these histone marks are primarily mitotic. However, the
almost undetectable levels of H3 phosphorylations in G1- and
S-phase cells prevented us from concluding about their
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Figure 1 Screen for DNA-damage-responsive histone modiﬁcations. (A) U2OS cells were untreated (Untr) or treated with 2mM HU for 24h or
with 60mg/ml phleomycin (Phleo) for 2h. Cells were split into two samples, one being used for the acid extraction of histones that were
analysed in (B) and one sample for whole cell Laemmli extracts, which were analysed by western blotting with the indicated antibodies in (A).
(B) Coomassie staining of recombinant histones (Rec) and acid-extracted histones from either untreated (Untr), HU-treated or phleo-treated
U2OS cells. (C) Antibody-based screen for DNA-damage-responsive histone PTMs. Samples from (B) were used for western blot analysis with
the antibodies described in Supplementary Table 1. The results were categorized as described in the text.
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Importantly, however, H3K9Ac and H3K56Ac were reduced
after DNA damage in mitotic and G1/S-phase cells. Thus,
H3K9 and H3K56 acetylation levels do not change dramati-
cally throughout the cell cycle and, moreover, these modiﬁ-
cations respond to DNA damage in various cell-cycle stages.
As a complementary approach to study H3 phosphoryla-
tions, we used immunoﬂuorescence microscopy to visualize
the effects of DNA damage on these PTMs in nocodazole-
arrested cells (unfortunately, antibodies against H3K9Ac and
H3K56Ac were not effective in immunoﬂuorescence micro-
scopy experiments, precluding their use in such analyses).
Mitotic cells contain highly condensed chromosomes that
stain brightly with DAPI compared with the larger, less
brightly DAPI-stained, interphase cells. Consistent with our
other data, H3S10p, H3T11p, H3S28p and H3.3S31p were
highly enriched in mitotic cells compared with interphase
cells (Figure 3B). However, neither the levels nor localization
patterns of these modiﬁcations changed after DNA damage
(Figure 3B), conﬁrming that H3S10p, H3T11p, H3S28p and
H3.3S31p are largely restricted to mitosis and are not per-
ceptibly inﬂuenced by DNA damage in this phase of the cell
cycle. By using higher exposures, we found that H3S10p and
H3T11p were also detectable in interphase cells, where they
co-localized in a punctate, nuclear-staining pattern. However,
in line with our other data, this staining pattern was un-
changed by DNA damage (Figure 3C). As a ﬁnal approach to
investigate whether H3T11p changes in response to DNA
damage, we generated tracks containing high levels of local
DNA damage in U2OS cell nuclei by laser microirradiation.
This revealed that H3T11p was not recruited to nor excluded
from the damaged regions, which were detected by staining
for the DDR protein 53BP1 (Figure 3D; note the equivalent
overall H3T11p-staining patterns in undamaged and micro-
irradiated cells). Taken together, these ﬁndings led us to
conclude that, like the other H3 phosphorylations studied,
H3T11p is not an early DNA-damage-responsive histone
modiﬁcation in our system, which is in contrast to the
conclusions presented in a recent report (Shimada et al,
2008).
H3K9Ac and H3K56Ac are DNA-damage-responsive
histone PTMs
Histone modiﬁcations are best characterized for their invol-
vement in transcription, and DNA damage can inhibit this
process (Gentile et al, 2003; Kruhlak et al, 2007). We, there-
fore, concluded that the reductions we observed for H3K9Ac
and H3K56Ac in response to DNA damage might reﬂect an
indirect effect of transcriptional inhibition. To explore this
possibility, we treated cells with the RNA polymerase II
(Pol II) inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimi-
dazole (DRB). This agent inhibits kinases responsible for
phosphorylating Ser-2 and Ser-5 in the C-terminal domain
of the Pol II largest subunit, thus preventing transcriptional
elongation (Hirose and Ohkuma, 2007). As expected, DRB
treatment reduced Pol II Ser-2 and Ser-5 phosphorylation and
abolished the slower migrating, hyper-phosphorylated form
of Pol II on SDS-polyacrylamide gels (Figure 4A;
Supplementary Figure 3A). Effective transcriptional inhibi-
tion by DRB was also conﬁrmed by the loss of ﬂuoro-
deoxyuridine (FdU) incorporation (Supplementary Figure
3B). Signiﬁcantly, we observed no decrease in H3K9Ac or
H3K56Ac under these conditions (Figure 4A), indicating that
A
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Figure 2 Analysis of DDR-responsive histone PTMs. (A) Analysis of histone PTMs in U2OS or Hela cells. Left panels, U2OS cells were treated
with the indicated DNA-damaging agents (see Materials and methods for details) and analysed by western blotting of whole cell Laemmli
extracts with the indicated antibodies. Right panels, Hela cells were untreated or treated with 60mg/ml of phleomycin and analysed as
described for U2OS cells. (B) Cell-cycle analysis of histone PTMs. U2OS cells were synchronized at the G1/S-transition by a double-thymidine
procedure and subsequently released into the cell cycle. Samples were taken at indicated time points and cell-cycle distributions were
determined by FACS analyses. A sample from asynchronous (Asyn) cells is shown as a control. These samples were additionally subjected to
western blot analyses of whole cell Laemmli extracts and probed with the indicated antibodies.
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on overall H3K9 and H3K56 acetylation levels.
If lowered H3K9Ac and K56Ac levels reﬂect the presence of
DNA damage, one might expect that these histone PTMs
would revert to normal levels once the DNA damage has
been repaired. To test this, we treated cells acutely with
phleomycin for 2h and then collected the samples derived
from whole cell Laemmli extracts at various time points after
transferring the cells into fresh medium lacking phleomycin
to allow DNA repair to occur. This revealed that H3K9Ac and
H3K56Ac remained reduced compared with untreated sam-
ples for 2–4h after DNA-damage induction, whereas gH2AX
levels remained high during this time frame (Figure 4B; note
that samples were equally loaded as revealed by immuno-
blotting for histone H3 and H3K14Ac, a non-DNA-damage-
responsive histone modiﬁcation). However, at 8 and 24h
after phleomycin treatment, gH2AX levels decreased,
whereas H3K9 and H3K56 acetylation increased to levels
nearing those in untreated cells (Figure 4B). Collectively,
these results established that loss of gH2AX, which is asso-
ciated with DNA repair in mammalian cells, correlates with
the restoration of normal H3K9 and H3K56 acetylation levels.
We next determined the behaviour of H3K9Ac and
H3K56Ac during a time course of chronic phleomycin treat-
ment. Strikingly, this revealed that H3K9 and H3K56 acetyla-
tion could be reduced very rapidly, with near-maximal
reductions being observed just 15min after phleomycin addi-
tion (Figure 4C). We have been able to observe global
reductions in acetylation levels of H3K9 and H3K56 more
rapidly. Quantiﬁcation of H3K9Ac and H3K56Ac showed an
B50% reduction in levels compared with untreated amounts
(Supplementary Figure 4A). The amount of reduction in
H3K9Ac and H3K56Ac after DNA damage at short-time
intervals were consistent with the levels observed after 2h
of both phelomycin and UV treatments (compare
Supplementary Figure 4A with 4B). In Figure 4C, we found
that acetylation levels of H3K9 and H3K56 contrasted to
gH2AX levels, which increased progressively over time to
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Figure 3 Mitotic H3 phosphorylations are unaltered by DNA damage. (A) H3 phosphorylation levels, but not acetylation levels, are unaffected
by DNA damage. U2OS cells were arrested in pro-metaphase with nocodazole, then were either kept in nocodazole (Noc; M-phase) or released
from nocodazole for 6h (Noc & Rel; G1/S-phase) and subsequently either mock or phleomycin treated. Samples were analysed as in Figure 2.
(B) Immunoﬂuorescence analysis of H3 phosphorylations in mitosis. Nocodazole-arrested U2OS cells were left untreated or treated with
phleomycin and analysed by immunoﬂuorescence with the indicated antibodies. Induction of DNA damage was visualized by gH2AX staining
and the nucleus by DAPI staining of DNA. (C) Analysis of H3S10p and H3T11p in interphase cells. U2OS cells were untreated or treated for 2h
with phleomycin and analysed by immunoﬂuorescence for H3S10p and H3T11p. The enlarged section depicts punctuate co-localized staining
of H3S10p and H3T11p. Note the loss of brightly stained mitotic cells in phleomycin-treated cell populations. (D) H3T11p is unaffected in cells
containing concentrated tracks of DNA damage. U2OS cells were microirradiated to induce tracks containing DNA damage. Cells were allowed
to recover for 2h before ﬁxation and subsequent dual staining for 53BP1 and H3T11p. Inset shows a zoomed section of the damaged area.
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increase was most likely due to the spreading of gH2AX
surrounding DSBs, as well as constant DSB formation caused
by the presence of phleomycin). Therefore, the reduction of
H3K9Ac and H3K56Ac is quick and corresponds with the
appearance of gH2AX, but is not directly proportional to
gH2AX levels, as maximal reductions in H3K9Ac and
H3K56Ac were reached before maximal levels of gH2AX
were observed. Although other possibilities exist, these data
suggest that the loss of H3K9Ac and H3K56Ac after DNA
damage is not limited to sites of DNA damage, but rather
occurs as a more global response to DNA damage.
Initiation of the DDR involves activation of the PIKK-family
protein kinases, ATM, ATR and DNA-PK. As these kinases
impinge on many processes, including transcription and
checkpoint activation, and are required for effective DNA
repair, they represented good candidates for initiating and
transducing signals that would result in reduction of H3K9Ac
and H3K56Ac levels. To investigate this possibility, we treated
cells with the speciﬁc ATM inhibitor Ku-55933 (Hickson et al,
2004) or with the broad PIKK inhibitor wortmannin (Powis
et al, 1994). Intriguingly, both inhibitors reproducibly re-
duced H3K9Ac and H3K56Ac levels in non-DNA-damage-
treated cells (Figure 4D). Moreover, in the presence of these
PIKK inhibitors, H3K9Ac and H3K56Ac levels were no longer
reduced by phleomycin treatment (Figure 4D; as expected,
gH2AX was generated on phleomycin treatment in a
manner that was impaired by PIKK inhibition).
Additionally, depletion of ATM using small-interfering RNAs
(siRNAs) gave similar results (Supplementary Figure 5). One
interpretation of these data is that ATM and possibly other
PIKK-family members control H3K9Ac and H3K56Ac levels
even in the absence of exogenous DNA damage.
Alternatively, it may be that DNA damage affects these
PTMs by PIKK-independent mechanisms and that treating
cells with PIKK inhibitors leads to endogenous genotoxic
stress that is, in itself, sufﬁcient to trigger reduced H3K9Ac
and H3K56Ac levels.
To use a more quantitative and complementary method for
evaluating the effect of DNA damage on H3K56 acetylation,
we sought to ﬁnd regions in the genome that contained
H3K56Ac and could, therefore, be analysed by chromatin
immunoprecipitation (ChIP). It has been shown earlier that
the CDK1 and CYCLIN B1 promoter regions contain high
levels of H3K9Ac, which are reduced after DNA damage
(Shimada et al, 2008). As our data had established a strong
correlation between H3K9Ac and H3K56Ac levels, we used
ChIP to analyse the presence of H3K56Ac at the CDK1 and
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Figure 4 H3K9Ac and H3K56Ac decrease rapidly and reversibly upon DNA damage. (A) Transcriptional inhibition does not affect H3K9Ac and
H3K56Ac levels. Cells were treated for 2h with DRB, a Pol II transcription inhibitor, and analysed for H3K9Ac and H3K56Ac as described for
Figure 2. (B) Dynamics of changes in H3K9Ac and H3K56Ac levels are reciprocal to those of gH2AX. Recovery dynamics of H3K9Ac and
H3K56Ac levels were measured by acute treatment of U2OS cells with phleomycin for 2h and subsequently releasing them into phleomycin-
free medium. Samples were taken at the indicated time points and analysed using whole cell Laemmli extracts with the indicated antibodies.
H3K14Ac was included to control for a DDR-independent histone acetylation, gH2AX to detect DNA-damage induction and H3 for loading.
(C) H3K9Ac and H3K56Ac levels decrease rapidly upon DNA damage. U2OS cells were chronically treated with phleomycin and samples were
taken at the indicated times and analysed as in A. (D) PIKK inhibition reduces H3K9 and H3K56 acetylation. U2OS cells were pre-incubated for
1h with or without KU-55933, or wortmannin, then analysed as in A. (E) H3K56Ac levels are reduced at promoters of cell-cycle regulatory
genes upon DNA damage. Schematic representation of CYCLIN B1 and CDK1 genes showing positions analysed by ChIP followed by real-time
qPCR. U2OS cells were untreated or treated with phleomycin or 2h, before analyses by ChIP. Data represents percentage of IPed H3K56Ac
signal normalized to IPed H3 signal at the indicated genomic loci. Data represent the average of three independent experiments and error bars
show the standard deviation between these experiments.
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(Shimada et al, 2008), H3K56Ac was enriched on CDK1
and CYCLIN B1 promoter regions as compared with the
body of these genes (Figure 4E; Supplementary Figure 6A).
Moreover, consistent with our western blotting data, we
observed a 3–4 fold reduction in H3K56Ac levels on
phleomycin-induced DNA damage using ChIP analysis
(Figure 4E). Importantly, these results were not limited
to DNA-damage-repressible genes as further analysis of
additional, non-DNA-damage-responsive genes gave similar
reductions in H3K56Ac levels upon DNA damage
(Supplementary Figure 6B). To look at chromatin-bound
histones using another method, we analysed Triton-resistant
cell extracts either untreated or treated with phleomycin.
Consistent with the other methods, this revealed that
both H3K9Ac and H3K56Ac levels were reduced upon DNA
damage (Supplementary Figure 7). Taken together, these
ﬁndings, therefore, strongly support our other data indicating
that levels of chromatin-associated H3K56Ac decrease when
DNA is damaged.
Human GCN5/KAT2A acetylates H3K9 and H3K56
In yeast, acetylation of H3K56 is accomplished by Rtt109
(also termed KAT11), a HAT with no known homologues in
higher eukaryotes (Collins et al, 2007; Driscoll et al,2 0 0 7 ;
Han et al, 2007; Xhemalce et al, 2007). Although it has been
generally assumed that H3K56Ac does not exist in human
cells (Xu et al, 2005), the recent identiﬁcation of human
H3K56Ac by mass spectrometry and ChIP analysis has cast
doubt on this assumption (Garcia et al, 2007; Xie et al, 2009).
Interestingly, Saccharomyces cerevisiae Rtt109 was recently
shown to additionally catalyse H3K9 acetylation, a histone
PTM that is also generated by the HAT GCN5 (Fillingham
et al, 2008). In light of this, and because we noted that
both H3K9Ac and H3K56Ac lie within a Lys-Ser-Thr
motif (Figure 5A), we speculated that human GCN5
(hGCN5, also named KAT2A) might acetylate H3K56. To
test this idea, we puriﬁed recombinant hGCN5 and
analysed its activity towards recombinant human histone
H3.1 (Rec. H3), detecting products with antibodies directed
against H3K9Ac or H3K56Ac. As positive controls, we also
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Figure 5 hGCN5 acetylates H3K9 and H3K56 in vitro and in vivo.( A) The H3K9 and H3K56 motifs share sequence similarity. (B) Human GCN5
acetylates H3K9 and H3K56 in vitro. HAT activity towards H3K9 and H3K56 was assessed with puriﬁed S. cerevisiae and S. pombe Rtt109
(ScRTT109 and SpRTT109, respectively) or human GCN5 (hGCN5) in an in vitro HAT-assay containing puriﬁed human recombinant histone
H3.1 (Rec. H3) with subsequent analysis by western blotting with the indicated antibodies. SpClr4 was used as a non-HAT enzyme and a
ponceau staining of Rec. H3 is shown as a loading control. (C) H3K9Ac antibody is speciﬁc. Puriﬁed SpRtt109 was incubated with Rec.H3 or
Rec. H3 containing a Lys9 to Ala mutation (H3K9A) and analysed as in A. (D) H3K56Ac antibody is speciﬁc. Experiments were done as in B
except Rec. H3K56A was used instead of Rec. H3K9A. (E) hGCN5 is involved in acetylation of H3K9 and H3K56 in vivo. U2OS cells were
transfected with siRNAs against luciferase (siLuc) or GCN5 (siGCN5) and samples were analysed after 48h by western blotting of whole cell
Laemmli extracts with the indicated antibodies. (F) GCN5 depletion leads to the loss of H3K56Ac at promoters of cell-cycle regulatory genes.
U2OS cells were transfected as in E and analysed as in Figure 4E.
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Schizosaccharomyces pombe Rtt109, and as a negative con-
trol, we used S. pombe histone methyl-transferase Clr4.
Notably, as was the case for the two Rtt109 enzymes,
hGCN5 mediated the acetylation of both H3K9 and H3K56
(Figure 5B). Because of the potential for antibody non-
speciﬁcity, as well as cross-reactivity between H3K9Ac and
H3K56Ac, we next carried out similar assays with wild-type
histone H3 and with H3 derivatives bearing Lys-to-Ala
mutations on either Lys-9 or Lys-56 (Rec. H3K9A and Rec.
H3K56A, respectively). Importantly, these studies revealed
that the H3K9Ac and H3K56Ac antibodies were indeed
highly speciﬁc. Thus, the signal for H3K9Ac, but not
H3K56Ac, was abolished when Rec. H3K9A was used as a
substrate, whereas the signal for H3K56Ac, but not H3K9Ac,
was lost when Rec. H3K56A was used (Figure 5C and D,
respectively; note that no signal was observed when HAT
assays were carried out in the absence of acetyl-CoA). Taken
together, these data, therefore, established that hGCN5 can
act as an H3K56 HAT in vitro.
To test whether hGCN5 contributes to H3K56 acetylation
in vivo, we treated U2OS cells with a control siRNA or
with a pool of siRNAs directed against hGCN5. Western
blotting analysis revealed that hGCN5 depletion led to
reproducible reductions in both H3K9Ac and H3K56Ac
levels, indicating that hGCN5 promotes the formation
of these PTMs in vivo (Figure 5E). As shown in
Supplementary Figure 8A, similar effects were produced
when we used a different siRNA targeting GCN5.
Furthermore, hGCN5 depletion, using different siRNAs
targeting GCN5, also led to a substantial reduction of
H3K56Ac at the CDK1 and CYCLIN B1 promoter regions as
assessed by ChIP analysis (Figure 5F; Supplementary
Figure 8B). Importantly, hGCN5 depletion did not
result in DNA damage as assessed by gH2AX formation,
suggesting that the observed decreases in H3K9Ac and
H3K56Ac were speciﬁc and were not caused indirectly as a
consequence of DNA-damage induction (Supplementary
Figures 8C and 10). In addition, siGCN5 cells did not
exhibit an aberrant cell-cycle proﬁle or a loss in other
transcriptionally active histone marks, suggesting that the
reduced levels of H3K56Ac were a direct effect of GCN5
depletion and not an indirect effect caused by transcriptional
repression (Supplementary Figures 9B and 10). As structural
studies have suggested a homology between budding yeast
Rtt109 and human p300, we analysed the effects of p300
depletion on the levels of H3K9Ac and H3K56Ac.
Interestingly, knockdown of p300 resulted in a decrease in
both H3K9Ac and H3K56Ac, although to a lesser extent than
cells lacking GCN5 (Supplementary Figure 10). However,
unlike GCN5, the depletion of p300 induced DNA
damage as seen by an increase in gH2AX formation
(Supplementary Figure 10). Unfortunately, this result pre-
vents us from making a clear conclusion on the role of
p300 in the acetylation of H3K56. However, taken together,
our ﬁndings establish that hGCN5 is required for H3K56
acetylation in vivo. Although the incomplete nature of these
reductions might reﬂect residual hGCN5 activity, it could also
be that hGCN5 is just one of the several HATs that can target
these sites, which is consistent with known redundancies
between H3K9Ac HATs in various organisms (Kouzarides,
2007).
Discussion
Histone modiﬁcations have been proposed to dynamically
regulate chromatin functions in all DNA-based processes
(Kouzarides, 2007). We examined this hypothesis with re-
spect to the DDR and report our ﬁndings from a large-scale
antibody-based screen for histone modiﬁcations that are
responsive to DNA damage. Perhaps surprisingly, the major-
ity of histone modiﬁcations we analysed do not change
detectably after genotoxic stress, even though these condi-
tions are likely to affect transcription, a process intimately
linked to the maintenance and utilization of histone PTMs
(Berger, 2007; Kouzarides, 2007). Nonetheless, as discussed
below, we were able to identify two classes of histone modi-
ﬁcations whose global levels decrease upon DNA-damage
induction: H3 phosphorylations on Ser-10, Ser-28 and Ser-31,
together with H3 acetylations on Lys-9 and Lys-56.
Despite our initial ﬁndings and earlier reports implicating
H3 phosphorylations in the DDR (Allison and Milner, 2003;
Ito, 2007), our subsequent investigations have indicated that
H3S10p, H3S28p and H3S31p are not primarily responsive to
DNA damage per se, but, instead, their levels are reduced
mainly by indirect mechanisms. Speciﬁcally, it seems that
loss of these marks on DNA damage mainly reﬂects DNA
damage inducing G2/M arrest, thus reducing the proportion
of mitotic cells, a cell-cycle phase where these PTMs are most
abundant. Consistent with this, we found that H3S10p,
H3S28p and H3S31p levels did not change in response to
DNA damage when we speciﬁcally analysed mitotic cell
populations. Furthermore, and in contrast to an earlier
study (Shimada et al, 2008), we do not detect a speciﬁc effect
of DNA damage on H3T11p levels. Nevertheless, it is note-
worthy that we have found that H3T11p co-localizes with
H3S10p in interphase cells, raising the possibility that H3T11p
is associated with transcription, a process linked with H3S10p
in interphase (Cheung et al, 2000; Metzger et al, 2008;
Shimada et al, 2008).
In contrast to the H3 phosphorylations, our data indicate
that reductions in H3K9 and H3K56 acetylation in response to
DNA damage do not simply reﬂect indirect, cell-cycle effects.
Although the presence of H3K9Ac is well established in
mammalian cells, characterization of H3K56Ac has thus far
been limited to yeast, and its existence in human cells has
been uncertain (Xu et al, 2005; Miller et al, 2006). Neverthe-
less, mass spectrometry-based studies have recently shown
that H3K56 is both monomethylated and acetylated in human
cells. Additionally, H3K56Ac has been found to mark both
active and inactive genes in human embryonic stem cells (Xie
et al, 2009). These facts, along with our data, clearly show
the existence of H3K56Ac, which now raises questions about
the functions of modiﬁed H3K56 in human cells (Peters
et al, 2003; Freitas et al, 2004; Garcia et al, 2007). In yeast,
H3K56Ac is abundant, occurs in S-phase on newly synthe-
sized histones and is required for DNA-damage tolerance
through a role in chromatin assembly (Masumoto et al,
2005; Driscoll et al, 2007; Xhemalce et al, 2007; Chen et al,
2008; Li et al, 2008). However, S-phase-speciﬁc histone
acetylations have not been detected in human cells, suggest-
ing that this function of H3K56Ac might have been lost in
higher eukaryotes (Shahbazian and Grunstein, 2007).
Additionally, our cell-cycle analysis suggests that H3K56Ac
is not induced in S-phase in human cells, a ﬁnding shared
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et al, 2009). Notably, H3K56Ac has also been linked with
transcription in yeast (Xu et al, 2005; Schneider et al, 2006),
raising the possibility that such a function is conserved in
human cells. Our data, along with a genome-wide analysis in
human cells (Xie et al, 2009), has now established that
H3K56Ac is enriched on promoter regions of both active
and inactive genes (Figure 4E; Supplementary Figure 6).
Global analysis of H3K9Ac places this histone PTM predomi-
nantly at promoter regions of active genes (Kouzarides, 2007;
Wang et al, 2008), and it has been implicated in regulating
transcriptional repression after DNA damage (Shimada et al,
2008). Therefore, given the similarity between the sequence
contexts and physiological behaviours of H3K9Ac and
H3K56Ac, and probably the HATs targeting these sites (see
below), it is tempting to speculate that these marks share
a common function. In support of this idea, we have found
that, like H3K9Ac, H3K56Ac becomes diminished at pro-
moter regions of both cell-cycle responsive and active genes
in response to DNA damage (Figure 4E; Supplementary
Figure 6).
While this paper was under review, a seemingly contra-
dictory paper was published reporting that H3K56Ac in-
creases in human cells in response to DNA damage and
localizes to sites of damaged DNA (Das et al, 2009). One
potential explanation for these discrepancies was that our
experiments were performed with an antibody from Upstate
directed against H3K56Ac, whereas Das et al used a different
antibody from Epitomics. Additionally, our doses of DNA-
damaging agents were orders of magnitude lower than those
used in Das et al. For example, our treatments for HU and UV
were 2mM and 20J/m
2, respectively, whereas Das et al used
150mM HU and 49995J/m
2. Although these differences
might have explained the differential effects reported by
Das et al and ourselves, we have performed similar and
additional experiments with the Epitomics antibody, and in
no case have we been able to detect any increase of H3K56Ac
after DNA damage or H3K56Ac localization with sites
of DNA damage (JVT and KMM, unpublished data).
Unfortunately, we are, therefore, unable at this time to offer
an explanation for the discrepancies between our data and
those of Das et al.
A key question arising from our work is which HAT(s)
target H3K56 in vivo? The structure of Rtt109, the HAT that
targets both H3K56 and H3K9 in yeast, has recently been
solved (Fillingham et al, 2008) and is most similar to human
p300 (Tang et al, 2008). Although p300, like hGCN5, can
target lysines in the N-terminal tail of H3, it has poor in vitro
activity towards H3K56 (Tang et al, 2008). Our in vivo
analysis of p300 and its role in H3K56Ac were inconclusive
as, although reductions in H3K56Ac and H3K9Ac were ob-
served, cells lacking p300 exhibited DNA damage, which
could explain the reduced levels of these histone marks in
these cells (Supplementary Figure 10). The catalytic residues
of S. cerevisiae Rtt109 required for its HATactivity have been
identiﬁed (Tang et al). Surprisingly, S. cerevisiae Rtt109 shares
only 27% identity with S. pombe Rtt109, the only other HAT
for H3K56 that has been described to date, and the catalytic
residues in S. cerevisiae Rtt109 are poorly conserved in
human p300 (Xhemalce et al, 2007; Tang et al, 2008).
Collectively, these data suggest that the HATs responsible
for acetylation of H3K9 and H3K56 could be numerous and
divergent; and it remains to be established whether there is a
bona ﬁde Rtt109 homologue in mammals. Regardless, our
work has revealed that hGCN5 can promote the acetylation of
H3K56, as well as H3K9Ac, in human cells. Notably, like
H3K9Ac, hGCN5 has been implicated in the transcriptional
repression of the cell-cycle regulated genes CDK1 and
CYCLIN B1 after DNA damage (Shimada et al, 2008). Our
ChIPanalyses of H3K56Ac at the promoters of these genes are
consistent with H3K56Ac also being involved in this process,
as both DNA damage and depletion of hGCN5 resulted in
signiﬁcant reductions of H3K56Ac on these promoters
(Figures 4E and 5F). However, we also observe a reduction
in H3K56Ac on promoters of active genes that are not
repressed upon DNA damage (Supplementary Figure 6C) as
well as a reduction in cells depleted of GCN5, whereas these
cells were still able to cycle and had normal levels of CDK1,
CYCLIN B1 and transcriptionally active histone marks
(Supplementary Figure 9). Taken together, our data suggest
that low levels of H3K56Ac do not correlate directly with
repressed transcription, which is in accord with H3K56Ac
being found on promoters of numerous genes regardless of
their transcriptional status in human embryonic stem cells
(Xie et al, 2009).
Taking the above issues into consideration, it will be of
interest to determine whether the reductions of H3K9 and
H3K56 acetylation in response to DNA damage are caused by
DNA damage leading to the inhibition of hGCN5 or other
HATs for these sites. In line with such an idea, ChIP data have
shown that hGCN5 is lost from some promoter regions upon
DNA damage (Shimada et al, 2008). However, global or
microirradiation-induced DNA damage did not have a dis-
cernable effect on hGCN5 as assessed by immunoﬂuores-
cence, which could suggest that only a subset of hGCN5 is
affected by DNA damage (Supplementary Figure 8C and D).
Therefore, the precise relationship between hGCN5 and the
DDR awaits future investigation. Alternatively, or in addition,
DNA damage might enhance the activities of HDAC enzymes
for H3K9Ac and H3K56Ac. In this regard, it is noteworthy that
SIRT6, a member of the Sirtuin family of HDACs, deacetylates
H3K9Ac in mammalian cells (Michishita et al, 2008) and
that H3K56Ac is also deacetylated by Sirtuins in yeast (Celic
et al, 2006; Maas et al, 2006). However, cells lacking SIRT6
displayed normal global H3K9Ac levels (Michishita et al,
2008), and in addition, we found that over-expression or
siRNA-mediated depletion of SIRT6 had no detectable effect
on H3K9Ac or H3K56Ac levels in our system (JVT and
KMM, unpublished data). Additionally, though the use of
different classes of HDAC inhibitors all led to increased
H3K9 and H3K56 acetylation levels, only minor increases
were observed when using the Sirtuin-speciﬁc inhibitor
Nicotinamide (Supplementary Figure 11). Collectively, these
data allude to a redundancy of HDACs for H3K9Ac and
H3K56Ac. Interestingly, in S. pombe, the HDAC Clr6 deacety-
lates H3K9, and mutation of Clr6 or its S. cerevisiae homo-
logue Sin3, results in hyper-sensitivity to genotoxic stresses
(Jazayeri et al, 2004; Nicolas et al, 2007). Thus, in systems
where H3K9Ac and H3K56Ac have been studied, deregulation
of these histone marks results in an inability to tolerate DNA
damage. As subjecting human histone H3 to genetic analyses
is difﬁcult, deﬁning the precise functions of H3K9Ac and
H3K56Ac in the DDR is likely to represent a formidable
challenge.
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H3K9Ac and H3K56Ac in response to DNA damage is histone
eviction coupled with degradation. In yeast, histone turnover
has been shown to occur rapidly in promoter regions (Dion
et al, 2007). As we have found that H3K9Ac and H3K56Ac are
enriched in promoter regions (Figures 4E and 5F), these
acetylations could inﬂuence this process. However, the dy-
namics of histone turnover, either in the absence or presence
of DNA damage, in human cells, is unknown (Wang et al,
2008). Additionally, poly-ubiquitylation of H3 occurs after
DNA damage in human cells and ubiquitylation of H3/H4
was shown to destabilize nucleosomes in vitro, which could
favour eviction with subsequent degradation (Wang et al,
2006). Together, such events could potentially regulate
H3K9Ac and H3K56Ac levels after DNA damage.
Our work raises the important question of why DNA
damage speciﬁcally decreases the global levels of H3K9Ac
and H3K56Ac? Global responses to DNA damage have been
documented in various systems and have been shown to
impact on phenomena such as chromatin relaxation, gen-
ome-wide sister-chromatid cohesion, transcriptional repres-
sion as well as acetylation/deacetylation of proteins
(including histones) (Ramanathan and Smerdon, 1986;
Gentile et al, 2003; Ziv et al, 2006; Strom et al, 2007; Unal
et al, 2007). It will, therefore, be interesting to investigate the
potential role of H3K9Ac and H3K56Ac in these processes
both in the presence or absence of genotoxic stress. As HDAC
inhibitors are promising cancer therapeutic agents that have
been shown to radio-sensitize cancer cells (Cerna et al, 2006;
Camphausen and Toﬁlon, 2007), understanding the interplay
between DNA damage and histone acetylation could give
important insights into the mechanisms of these emerging
drugs for the treatment of cancers.
Materials and methods
Cell culture, reagents and treatments
Human U2OS and HeLa cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% foetal bovine
serum, 100U/ml penicillin, 100mg/ml streptomycin and 2mM
L-glutamine. Drug treatments were with MMS (Sigma, 3mM,
60min), phleomycin (Sigma, 60mg/ml, 2h), H2O2 (VWR Interna-
tional, 500mM, 30min) or CPT (Sigma, 1mM, 60min). Cells were
exposed to 15Gy of IR with a
137Cs source and subsequently placed
in a 371C incubator for recovery for 1h. UV treatments were at 20J/
m
2 followed by recovery for 1h. Wortmannin (Alexis Biochemicals,
50mM, 0.5h pre-incubation) and ATM inhibitor (KU-55933, KuDOS
Pharmaceuticals, Cambridge, UK, 25mM, 0.5h pre-incubation)
were used to inhibit PIKKs. HDAC inhibitors were added for 24h
and ﬁnal concentrations were as follows: sodium butyrate (5mM),
TSA (1.3mM) or Nicotinamide (20mM). Primary histone antibodies
used in this study are listed in Supplementary Table 1. Cell-cycle
analyses of U2OS cells were done with a double-thymidine block-
and-release procedure. To arrest in G1/S, cells were treated for
18h with 3mM thymidine (Sigma). Cells were washed three times
with PBS and placed in fresh medium to release cells back into the
cell cycle. After 12h, cells were again treated with 3mM thymidine
containing DMEM for an additional 18h. Cells were again released
into the cell cycle by washing three times with PBS and adding fresh
medium, and samples were taken at the indicated time points by
harvesting cells with trypsin. One-ﬁfth of the cells was used for
FACS analysis and the rest was subjected to Laemmli lysis buffer
to generate whole cell extracts (WCEs) (see below). For pro-
metaphase synchronization, cells were incubated for 18h with
DMEM medium containing 0.1mg/ml of nocodazole (Fisher
Scientiﬁc). Cells were harvested as described above and analysed
by FACS and western blotting with the indicated antibodies.
Transcriptional inhibition was accomplished by treating cells for
2h with the RNA Pol II inhibitor DRB (75mM stock in DMSO) at a
ﬁnal concentration of 100mM. Cells were either analysed by western
blotting with the indicated antibodies or analysed by immuno-
ﬂuorescence. For immunoﬂuorescence, after 2h of DRB treatment,
cells were incubated in 1mM 5 FdU (50mM stock in PBS) for
15min. Cells were washed three times in PBS followed by ﬁxation
in 2% paraformaldehyde (PBS) for 20min at room temperature,
then washed three times with PBS and then permeabilized with
0.2% Triton in PBS for 5min at room temperature. Cells were
washed again three times in PBS, blocked for 20min in PBS
containing 3% BSA and then incubated in anti-BrdU antibody for
1h at room temperature. Cells were then analysed as described for
immunoﬂuorescence (see below). Non-histone primary antibodies
used were p53 Ser15-p (Cell Signaling), SMC1 Ser966-p (Bethyl
Laboratories), SMC1 (Bethyl Laboratories), 53BP1 (Novus Biologi-
cals), GCN5 (Cell Signaling), BrdU (Sigma), RNA Pol II (Santa
Cruz), Pol II Ser2-p (Abcam), Pol II Ser5-p (Abcam), CHK2 (Cell
Signaling), CHK2 T68p (Cell Signaling), ATM (kindly provided by
Yossi Shiloh’s Lab), p300 (Insight Biotechnology), CYCLIN-B1
(Pharmagen) and CDK1 (CRUK).
WCEs, site-directed mutagenesis and histone puriﬁcations
For WCEs, cells were washed once with PBS and collected by
trypsinization and centrifugation. Pellets were resuspended in
Laemmli buffer (4% SDS, 20% glycerol and 120mM Tris [pH
6.8]) and sheared through a 23-guage needle, boiled for 5min at
951C and again sheared with a needle. Triton-resistant extracts were
made by washing cells once with PBS followed by 5min on ice in
CSK buffer (10mM PIPES pH 6.8, 100mM NaCl, 300mM sucrose,
3mM MgCl2, 1mM EGTA, 0.5% TritonX-100). Cells were washed
three times in cold-PBS, scraped in Laemmli buffer, sheared through
a 23-gauge needle and ﬁnally boiled for 5min before loading.
Human core histones, H2A, H2B, H3.1 and H4 were cloned into
pET21 and puriﬁed from Escherichia coli inclusion bodies as
described earlier (Luger et al, 1999). Lys9 and Lys56 were mutated
in H3.1 by standard techniques and mutated proteins puriﬁed as for
wild-type H3.1. Acid extraction of histones was essentially
performed as described (Shechter et al, 2007). Brieﬂy, approxi-
mately 5 10
6 cells were collected by trypsinization and centrifuga-
tion, washed once with PBS, then the cell pellet was resuspended in
1ml of hypotonic lysis buffer (10mM Tris pH 8.0, 1mM KCl, 1.5mM
MgCl2, 1mM dithiothreitol, 10mM Na-butyrate, 20mM N-ethylma-
leimide, phosphatase inhibitors and protease inhibitor cocktail) and
incubated for 30min at 41C to promote hypotonic swelling. The
cells were then recovered by centrifugation, resuspended in 400ml
of 0.4M H2SO4 and incubated on a rotator for 30min at 41C. After
centrifugation, the supernatant was dialysed overnight at 41C
against 4l of distilled water supplemented with 40mlo fb-mercapto-
ethanol. Samples were analysed using standard western blotting
techniques. Quantiﬁcation was performed, if indicated, using a LI-
COR Odyssey infrared imaging system (LI-COR Biosciences), where
densitometry values were calculated for various histone marks and
normalized to H3 values. Secondary antibody used for quantiﬁca-
tion was IRDye 680CW Donkey anti-rabbit (LI-COR Biosciences).
siRNA transfection
RNA-interference was performed with the HiPerfect (Qiagen)
transfection reagent as suggested by the manufacturer. U2OS cells
were transfected at 25% conﬂuency with siGCN5 (CCUUAGAGGG
AAUAAUAAA) or siGCN5 smartpool from Dharmacon, sip300
(AACCCCUCCUCUUCAGCACCA), siATM (GACUUUGGCUGUCAAC
UUUCG) or siLuciferase (CGUACGCGGAAUACUUCGA) at a ﬁnal
concentration of 5nM. Transfections were repeated after 24h,
and samples were taken after an additional 24h for GCN5 and
ATM siRNAs or 48h for p300 siRNA. Western blot analyses with
the indicated antibodies were performed to analyse depletion
efﬁciency.
Chromatin immunoprecipitation
In vivo cross-linking, chromatin puriﬁcation and immunoprecipita-
tions were performed as described earlier (Orlando et al, 1997). The
average fragment size of soluble chromatin fragments after
sonication was B500bp. Antibodies used for immunoprecipitations
are listed in Supplementary Table 1. Primers used for qPCR for
different loci are listed in Supplementary Table 2.
Screen for DNA-damage-responsive histone modiﬁcations
JV Tjeertes et al
&2009 European Molecular Biology Organization The EMBO Journal VOL 28 | NO 13 | 2009 1887Immunoﬂuorescence microscopy
U2OS cells were grown on poly-L-lysine-treated coverslips. For
induction of DNA damage, cells were incubated with 60mg/ml
phleomycin for 2h. Pro-metaphase-arrested cells were obtained by
overnight incubation in 0.1mg/ml of nocodazole. Once treated,
coverslips were washed once with 1  PBS at room temperature.
Cells were then pre-extracted by incubating the coverslips in CSK
buffer (10mM PIPES pH 6.8, 100mM NaCl, 300mM sucrose, 3mM
MgCl2, 1mM EGTA, 0.5% TritonX-100) for 5min on ice. Cells were
washed once in cold-PBS and ﬁxed with 2% paraformaldehyde for
15min at room temperature followed by three washes with 1  PBS
containing 0.1% Tween-20 (PBS-T) and subsequently blocked for
15min at room temperature in blocking buffer (PBS-T, 3% BSA).
Primary antibodies were incubated for 1h at room temperature in the
same buffer. Cells were washed three times in wash buffer (PBS-T)
before incubation in the dark with Alexa-conjugated secondary
antibodies (Molecular Probes) in blocking buffer for 1h at room
temperature. Cells were again washed three times in PBS-T followed
by a ﬁnal wash in PBS. The coverslips were then mounted on slides
in Vectashield containing DAPI (Vector laboratories). Cells were
imaged with an inverted FV1000 confocal microscope (Olympus).
For GCN5 staining in Supplementary Figure 5, cells were not pre-
extracted with CSK buffer, but were analysed identically as for DRB-
treated cells (see above).
HAT activity assay
Experiments were performed essentially as described before
(Driscoll et al, 2007). Recombinant S. cerevisiae RTT109, S. pombe
Rtt109 and human GCN5 (ScRtt109, SpRtt109 and hGCN5, respec-
tively) were puriﬁed as described before (Wang et al, 1997; Driscoll
et al, 2007; Xhemalce et al, 2007). Puriﬁed S. pombe Clr4 (SpClr4)
was kindly provided by B Xhemalce (T Kouzarides laboratory).
Reactions contained 1mg of recombinant human H3.1 and either
2mg SpRtt109, 1.2mg SpRtt109, 1.2mg SpClr4, 0.4mg hGCN5 or Rec.
H3.1 alone. Reactions were incubated for 45min at 301C. Samples
were boiled in an equal volume of 3  loading buffer (150mM
Tris–HCl pH 6.8, 350mM b-mercaptoethanol, 150mM DTT, 6% SDS,
30% glycerol and 0.1% bromophenol blue) and one-tenth of each
reaction was analysed by western blotting with the indicated
antibodies.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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